Completed Clinical Trials

Evaluation of AGN-150998 in Exudative AMD: Single Dose Study of the Safety and Efficacy of AGN-150998 in Patients with Exudative Age-Related Macular Degeneration


A Single Arm Open Label Study to Evaluate the Pharmacodynamics and Safety of a 4 Week Treatment With BI 144807 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration (wAMD)


A 24-Month, Phase IIIb, Open-Label, Single Arm, Multicenter Study Assessing the Efficacy and Safety of an Individualized, Stabilization Criteria-Driven PRN Dosing Regimen With 0,5 mg Ranibizumab Intravitreal Injections Applied as Monotherapy in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)


Safety and Efficacy Study of ESBA 1008 Versus Lucentis for the Treatment of Exudative Age-Related Macular Degeneration


VEGF Trap-Eye: Investigation of Efficacy and Safety in CRVO -A Randomized, Double-Masked, Sham-Controlled Phase III Study of Efficacy, Safety and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)


The Safety and Efficacy of AL-8309B Ophthalmic Solution for the Treatment of Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)


A Clinical Safety and Efficacy Comparison of NEVANAC 0,1% to Vehicle Following Cataract Surgery in Diabetic Retinopathy Patients


Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation to Assess the Safety and Efficacy of Nepafenac Ophthalmic Suspension, 0.3% for Improvement in Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery


A 24-Month, Phase IIIb, Randomized, Double-Masked, Multicenter Study Assessing the Efficacy and Safety of Two Treatment Regimens of 0,5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients with Neovascular Age-Related Macular Degeneration


A Phase II, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) Given in Combination With Lucentis in Subjects With Neovascular Age-Related Macular Degeneration


VEGF Trap-Eye: Investigation of Efficacy and safety in Wet AMDA Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap-eye in Subjects With Neovascular Age-Related Macular Degeneration (AMD)


A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap-Eye in Subjects With Diabetic Macular Edema


Wet AMD AL-39324 Treatment Examination:A Dose-Escalation of AL-39324 Suspension Versus Lucentis for the Treatment of Exudative Age-Related Macular Degeneration 


Influence of Sustained-Release Dexamethasone on Intraocular Cytokines and Growth Factors and Retinal Blood Vessels in Retinal Vein Occlusion


Management of Recurrent or Persistent Choroidal Neovascularization Secondary to Age-Related Macular Degeneration: A Prospective, Randomized, Clinical Study